Valiant Laboratories Ltd – From ₹127 Highs to ₹86 Headaches: Paracetamol Maker’s Fever Pitch
1. At a Glance
Valiant Laboratories Ltd (Valiant Lab for short, because even their balance sheet values brevity) is in the glamorous business of making paracetamol. Yes, the very pill you pop after scrolling 3 hours of smallcap Twitter threads. Once trading at ₹127, the stock now chills at ₹86, which is basically a fever chart turned upside down. With a P/E of 3,621 (no typo, no glitch, just math laughing at you), and a market cap of ₹471 crore, this is the desi version of “Why so serious?” in the pharma world.
2. Introduction
Valiant Laboratories was born in 1980, back when paracetamol was already a household name. Four decades later, guess what they still sell? Paracetamol. Imagine spending 40 years in school and still failing math – that’s how their innovation department looks.
But don’t underestimate them. They’ve built a 9,000 MTPA plant in Palghar, Maharashtra, and filled it with GMP and ISO 9001:2015 certificates. Fancy walls, white lab coats, and enough paperwork to make any auditor feel useful.
Still, their financials are like a comedy show: sales jumping 148% QoQ, profits growing 457%, but OPM at 0.06%—basically, they sell crores worth of medicine but end up with profits smaller than a chemist’s daily discount jar.
The share price tells the real story: down 20% in the past year. Investors who expected a Sun Pharma-like glow-up instead got stuck with an expired Crocin strip. And to add masala, CRISIL downgraded them (twice) while a safety violation literally cost someone’s life.
Question for you: Would you bet on a company whose entire empire depends on how many Indians wake up with headaches?
3. Business Model – WTF Do They Even Do?
In plain English: Valiant makes paracetamol API and sells it in powder, fine powder, and crystal forms. They also push it into tablets, capsules, and other dosage forms. That’s it. No diabetes drugs, no cutting-edge cancer molecules, not even an ayurvedic dabba. Just paracetamol – the McDonald’s french fries of pharma.
Revenue breakup FY24:
94% from manufactured products (basically paracetamol again).
1% other operating revenue (selling maybe dust from the factory floor).
2% interest income (from loans to their own subsidiary).
3% non-operating income (likely rent from idle assets or pure jugaad).
They even tried diversifying: in October 2023, they threw ₹165 crore into their subsidiary Valiant Advanced Sciences Pvt Ltd. The idea? “Advanced Sciences.” The outcome? Still waiting.
Fun fact: their IPO in October 2023 raised ₹152 crore. If you subscribed, congratulations—you funded the paracetamol party.
Question: Do you think India really needed another paracetamol maker in 2023?
4. Financials Overview
Metric
Latest Qtr (Jun ’25)
YoY Qtr (Jun ’24)
Prev Qtr (Mar ’25)
YoY %
QoQ %
Revenue
₹46.8 Cr
₹18.9 Cr
₹57.8 Cr
148%
-19%
EBITDA
₹2.4 Cr
-₹2.4 Cr
₹3.8 Cr
NA
-37%
PAT
₹1.82 Cr
-₹0.51 Cr
₹0.70 Cr
457%
160%
EPS (₹)
0.34
-0.09
0.13
NA
161%
Commentary: EPS annualized is ₹1.36, which gives us that “comic P/E” of 63x if you calculate sanely. But Screener shows 3,621 thanks to tiny trailing EPS. Basically, this stock’s P/E ratio is more volatile than your internet connection during IPL.
5. Valuation – Fair Value Range Only
Let’s humor the numbers.
P/E Method: If EPS annualized = ₹1.36, and industry P/E = 32.5 → Fair value range = ₹44–₹70.
EV/EBITDA Method: EV ~ ₹516 Cr, EBITDA (FY25 TTM) ~ ₹3.4 Cr → EV/EBITDA = 151x (ouch). Industry median ~20x → Value should be ~₹68 Cr EV → Fair price per share ~₹11–₹18.
